Regeneron Pharmaceuticals Company Profile (NASDAQ:REGN)

About Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals logoRegeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:REGN
  • CUSIP: 75886F10
  • Web: www.regeneron.com
Capitalization:
  • Market Cap: $47.75506 billion
  • Outstanding Shares: 106,033,000
Average Prices:
  • 50 Day Moving Avg: $456.72
  • 200 Day Moving Avg: $455.81
  • 52 Week Range: $325.35 - $543.55
P/E:
  • Trailing P/E Ratio: 44.40
  • Foreward P/E Ratio: 31.23
  • P/E Growth: 1.65
Sales & Book Value:
  • Annual Revenue: $5.24 billion
  • Price / Sales: 8.96
  • Book Value: $52.07 per share
  • Price / Book: 8.50
Profitability:
  • EBITDA: $1.82 billion
  • Net Margins: 22.05%
  • Return on Equity: 25.58%
  • Return on Assets: 16.63%
Debt:
  • Debt-to-Equity Ratio: 0.13%
  • Current Ratio: 3.75%
  • Quick Ratio: 3.21%
Misc:
  • Average Volume: 743,895 shs.
  • Beta: 1.62
  • Short Ratio: 3.33
 

Frequently Asked Questions for Regeneron Pharmaceuticals (NASDAQ:REGN)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its quarterly earnings results on Thursday, August, 3rd. The company reported $4.17 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.67 by $1.50. The business earned $1.47 billion during the quarter, compared to the consensus estimate of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm's revenue for the quarter was up 21.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.82 EPS. View Regeneron Pharmaceuticals' Earnings History.

When will Regeneron Pharmaceuticals make its next earnings announcement?

Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Regeneron Pharmaceuticals.

Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2017?

26 equities research analysts have issued twelve-month target prices for Regeneron Pharmaceuticals' stock. Their predictions range from $345.00 to $605.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $492.57 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals.

What are analysts saying about Regeneron Pharmaceuticals stock?

Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:

  • 1. Canaccord Genuity analysts commented, "Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible." (10/16/2017)
  • 2. According to Zacks Investment Research, "With Eylea accounting for the majority of revenues at Regeneron, Regeneron relies heavily on the drug for growth. In the U.S., the company is witnessing increased competitor discounts and rebates. Sub-par performance of the product will hurt the stock as Eylea is Regeneron’s key growth driver. Prospects of PCSK9 inhibitors, a new class of cholesterol-lowering treatments with blockbuster potential, gained instant popularity even before hitting the market. However, sales of Praluent have failed to impress as the drug is facing significant payer utilization management restrictions in the U.S. and limited market access in Europe, which is resulting in a low volume of prescriptions being dispensed. Nevertheless, the approval of new drugs like Kevzara and Dupixent provide a significant boost to the top-line. Shares have outperformed the industry so far in 2017." (10/10/2017)
  • 3. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017)
  • 4. Cowen and Company analysts commented, "REGN reported Q1:17 U.S." (5/5/2017)
  • 5. BMO Capital Markets analysts commented, "We raise our price target to $412 but maintain our Market Perform rating on REGN following Dupixent approval in adult atopic dermatitis. While the approval was widely expected and reflects the strength of Dupixent's clinical profile, we believe the $37k gross price (~$30k net) is higher than expected (BMO: ~$25k prior) and could lead to even more aggressive management by payors. Thus, while we have updated our model to reflect Dupixent's actual price, we have slowed our ramp on our expectation for increased access restrictions given the therapy's high price." (3/28/2017)

Who are some of Regeneron Pharmaceuticals' key competitors?

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the folowing people:

  • P. Roy Vagelos M.D., Chairman of the Board
  • Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director
  • Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance
  • Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply
  • Neil Stahl Ph.D., Executive Vice President - Research and Development
  • Robert J. Terifay, Executive Vice President - Commercial
  • Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary
  • Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation
  • Peter Powchik M.D., Senior Vice President - Clinical Development
  • George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director

Who owns Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Eqis Capital Management Inc. (0.00%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Douglas S Mccorkle, George Yancopoulos, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.

Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock?

Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have sold Regeneron Pharmaceuticals stock in the last year include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals.

How do I buy Regeneron Pharmaceuticals stock?

Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $442.56.


MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  975 (Vote Outperform)
Underperform Votes:  750 (Vote Underperform)
Total Votes:  1,725
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 14 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $492.57 (11.30% upside)
Consensus Price Target History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Price Target History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Analysts' Ratings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017J P Morgan Chase & CoReiterated RatingHoldN/AView Rating Details
10/16/2017Canaccord GenuityReiterated RatingBuyN/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$450.00 -> $490.00N/AView Rating Details
10/6/2017Jefferies Group LLCReiterated RatingHold$471.00 -> $500.00N/AView Rating Details
10/2/2017SunTrust Banks, Inc.Reiterated RatingHold$435.00MediumView Rating Details
9/29/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$540.00HighView Rating Details
9/27/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform -> Sector Perform$475.00MediumView Rating Details
9/11/2017Credit Suisse GroupReiterated RatingBuy$485.00LowView Rating Details
9/8/2017Robert W. BairdReiterated RatingSell$408.00LowView Rating Details
9/7/2017Citigroup Inc.Reiterated RatingBuy$575.00LowView Rating Details
9/6/2017Raymond James Financial, Inc.Reiterated RatingOutperform -> Outperform$566.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$605.00MediumView Rating Details
8/15/2017Leerink SwannReiterated RatingOutperform -> Positive$580.00 -> $552.00LowView Rating Details
8/9/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$469.00 -> $472.00LowView Rating Details
8/3/2017BMO Capital MarketsSet Price TargetHold$491.00LowView Rating Details
7/22/2017Barclays PLCReiterated RatingEqual Weight$400.00 -> $450.00LowView Rating Details
7/21/2017Bank of America CorporationReiterated RatingBuy$589.00 -> $593.00LowView Rating Details
6/30/2017BTIG ResearchReiterated RatingBuy -> Buy$480.00 -> $540.00HighView Rating Details
6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00LowView Rating Details
5/15/2017Cowen and CompanyReiterated RatingHold$380.00LowView Rating Details
3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
1/10/2017Wells Fargo & CompanyReiterated RatingMarket PerformN/AView Rating Details
1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/AView Rating Details
12/28/2016ArgusReiterated RatingBuy$450.00N/AView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$520.00N/AView Rating Details
8/5/2016Brean CapitalReiterated RatingBuy$489.00N/AView Rating Details
3/15/2016GabelliInitiated CoverageBuy$574.00N/AView Rating Details
(Data available from 10/18/2015 forward)

Earnings

Earnings History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Earnings History by Quarter for Regeneron Pharmaceuticals (NASDAQ REGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017$3.83N/AView Earnings Details
8/3/2017Q2 2017$2.67$4.17$1.36 billion$1.47 billionViewListenView Earnings Details
5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListenView Earnings Details
2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListenView Earnings Details
11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/AView Earnings Details
8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/AView Earnings Details
5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/AView Earnings Details
2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListenView Earnings Details
11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListenView Earnings Details
8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListenView Earnings Details
5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/AView Earnings Details
2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/AView Earnings Details
11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/AView Earnings Details
8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/AView Earnings Details
5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/AView Earnings Details
11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/AView Earnings Details
5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/AView Earnings Details
2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/AView Earnings Details
10/24/2012$1.14$1.89ViewN/AView Earnings Details
7/25/2012$0.45$0.90ViewN/AView Earnings Details
4/26/2012($0.33)$0.37ViewN/AView Earnings Details
2/13/2012($0.60)($0.37)ViewN/AView Earnings Details
7/28/2011($0.40)($0.69)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)
Current Year EPS Consensus Estimate: $13.77 EPS
Next Year EPS Consensus Estimate: $14.17 EPS

Dividends

Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Ownership Percentage: 10.80%
Institutional Ownership Percentage: 67.40%
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Insider Trades by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/5/2017Michael S BrownDirectorSell1,500$475.00$712,500.00View SEC Filing  
9/29/2017Charles A BakerDirectorSell2,000$450.00$900,000.00View SEC Filing  
9/6/2017Robert E LandrySVPSell663$498.60$330,571.80View SEC Filing  
9/5/2017Robert E LandryCFOSell189$501.06$94,700.34View SEC Filing  
8/31/2017Robert E LandrySVPSell427$493.43$210,694.61View SEC Filing  
8/25/2017SanofiMajor ShareholderBuy72,378$481.36$34,839,874.08View SEC Filing  
8/24/2017SanofiMajor ShareholderBuy166,415$480.93$80,033,965.95View SEC Filing  
8/23/2017Robert E LandrySVPSell468$476.45$222,978.60View SEC Filing  
8/22/2017P Roy VagelosChairmanSell56,213$474.48$26,671,944.24View SEC Filing  
8/18/2017P Roy VagelosChairmanSell15,191$470.15$7,142,048.65View SEC Filing  
8/17/2017P Roy VagelosChairmanSell1,305$470.00$613,350.00View SEC Filing  
8/16/2017P Roy VagelosChairmanSell10,986$470.17$5,165,287.62View SEC Filing  
8/8/2017Robert E LandrySVPSell526$472.19$248,371.94View SEC Filing  
6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.98View SEC Filing  
6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.30View SEC Filing  
6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.00View SEC Filing  
6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.93View SEC Filing  
6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.15View SEC Filing  
6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.00View SEC Filing  
6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.88View SEC Filing  
6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50View SEC Filing  
5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30View SEC Filing  
5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.00View SEC Filing  
3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.00View SEC Filing  
1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58View SEC Filing  
12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.00View SEC Filing  
11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.00View SEC Filing  
11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.00View SEC Filing  
7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.00View SEC Filing  
6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66View SEC Filing  
5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.00View SEC Filing  
5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.01View SEC Filing  
4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.00View SEC Filing  
3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.00View SEC Filing  
2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22View SEC Filing  
1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52View SEC Filing  
12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.32View SEC Filing  
12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00View SEC Filing  
12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44View SEC Filing  
11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00View SEC Filing  
11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55View SEC Filing  
11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.45View SEC Filing  
11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98View SEC Filing  
11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28View SEC Filing  
10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98View SEC Filing  
9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03View SEC Filing  
9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00View SEC Filing  
9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.00View SEC Filing  
8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30View SEC Filing  
7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00View SEC Filing  
6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00View SEC Filing  
5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81View SEC Filing  
5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40View SEC Filing  
5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00View SEC Filing  
5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00View SEC Filing  
5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00View SEC Filing  
3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00View SEC Filing  
3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57View SEC Filing  
3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00View SEC Filing  
3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93View SEC Filing  
3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00View SEC Filing  
2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00View SEC Filing  
2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00View SEC Filing  
2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91View SEC Filing  
2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42View SEC Filing  
2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00View SEC Filing  
2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32View SEC Filing  
1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00View SEC Filing  
1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76View SEC Filing  
12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39View SEC Filing  
12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90View SEC Filing  
11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00View SEC Filing  
11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51View SEC Filing  
11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98View SEC Filing  
11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50View SEC Filing  
11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00View SEC Filing  
11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10View SEC Filing  
10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12View SEC Filing  
10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00View SEC Filing  
10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60View SEC Filing  
9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42View SEC Filing  
9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80View SEC Filing  
9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96View SEC Filing  
8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00View SEC Filing  
8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00View SEC Filing  
8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00View SEC Filing  
8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00View SEC Filing  
8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00View SEC Filing  
8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28View SEC Filing  
8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16View SEC Filing  
8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92View SEC Filing  
8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60View SEC Filing  
8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22View SEC Filing  
8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00View SEC Filing  
7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00View SEC Filing  
7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00View SEC Filing  
7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00View SEC Filing  
7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00View SEC Filing  
7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00View SEC Filing  
7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00View SEC Filing  
6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00View SEC Filing  
5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.17View SEC Filing  
5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04View SEC Filing  
3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85View SEC Filing  
3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45View SEC Filing  
3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.00View SEC Filing  
3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95View SEC Filing  
3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30View SEC Filing  
3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99View SEC Filing  
3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.00View SEC Filing  
3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06View SEC Filing  
3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55View SEC Filing  
3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12View SEC Filing  
3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44View SEC Filing  
3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28View SEC Filing  
2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.00View SEC Filing  
2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00View SEC Filing  
2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.05View SEC Filing  
2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00View SEC Filing  
2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.58View SEC Filing  
2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.00View SEC Filing  
2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.16View SEC Filing  
2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.20View SEC Filing  
2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.84View SEC Filing  
2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.71View SEC Filing  
2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.00View SEC Filing  
2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00View SEC Filing  
2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00View SEC Filing  
2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.50View SEC Filing  
2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58View SEC Filing  
2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68View SEC Filing  
2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16View SEC Filing  
1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00View SEC Filing  
1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00View SEC Filing  
1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00View SEC Filing  
1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.36View SEC Filing  
12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.93View SEC Filing  
11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00View SEC Filing  
11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.00View SEC Filing  
9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.83View SEC Filing  
9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.16View SEC Filing  
9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.09View SEC Filing  
9/18/2013William RobertsVPSell15,000$304.00$4,560,000.00View SEC Filing  
9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00View SEC Filing  
8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.00View SEC Filing  
6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00View SEC Filing  
5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00View SEC Filing  
5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00View SEC Filing  
5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90View SEC Filing  
5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00View SEC Filing  
5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69View SEC Filing  
5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44View SEC Filing  
5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00View SEC Filing  
5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13View SEC Filing  
5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70View SEC Filing  
11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66View SEC Filing  
11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00View SEC Filing  
11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00View SEC Filing  
11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00View SEC Filing  
9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00View SEC Filing  
8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Regeneron Pharmaceuticals (NASDAQ:REGN)
Latest Headlines for Regeneron Pharmaceuticals (NASDAQ:REGN)
Source:
DateHeadline
nasdaq.com logoSanofi/Regeneron's Dupixent Succeeds in Phase II Study - Nasdaq
www.nasdaq.com - October 18 at 8:07 AM
investorplace.com logoQuant Score Limits Regeneron Pharmaceuticals (REGN) Rating - Investorplace.com (blog)
investorplace.com - October 18 at 8:06 AM
americanbankingnews.com logo$1.46 Billion in Sales Expected for Regeneron Pharmaceuticals, Inc. (REGN) This Quarter
www.americanbankingnews.com - October 17 at 11:12 AM
nasdaq.com logoRegeneron Pharma, Sanofi Announce Positive Phase 2 Study Results For Dupilumab - Nasdaq
www.nasdaq.com - October 17 at 6:42 AM
americanbankingnews.com logoCanaccord Genuity Reaffirms Buy Rating for Regeneron Pharmaceuticals, Inc. (REGN)
www.americanbankingnews.com - October 16 at 9:24 PM
investorplace.com logoQuant Score Limits Regeneron Pharmaceuticals (REGN) Rating
investorplace.com - October 16 at 4:34 PM
finance.yahoo.com logoInternationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
finance.yahoo.com - October 12 at 8:53 AM
finance.yahoo.com logoRegeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017
finance.yahoo.com - October 12 at 8:53 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 11 at 8:52 PM
investorplace.com logoRating on Regeneron Pharmaceuticals (REGN) Upgraded to Buy From a Hold - Investorplace.com
investorplace.com - October 11 at 7:02 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 10 at 10:14 AM
seekingalpha.com logoRegeneron Stock Shows Promise Despite High Valuation Multiple
seekingalpha.com - October 10 at 6:18 AM
finance.yahoo.com logoRegeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : October 9, 2017
finance.yahoo.com - October 10 at 6:18 AM
investorplace.com logoRating on Regeneron Pharmaceuticals (REGN) Upgraded to Buy From a Hold
investorplace.com - October 9 at 3:04 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Forecasted to Earn FY2020 Earnings of $18.59 Per Share
www.americanbankingnews.com - October 9 at 8:20 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 8 at 7:20 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Given Hold Rating at Jefferies Group LLC
www.americanbankingnews.com - October 7 at 2:24 PM
streetinsider.com logoRegeneron (REGN) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
www.streetinsider.com - October 7 at 7:52 AM
finance.yahoo.com logoRegeneron shares pop on cholesterol drug approval
finance.yahoo.com - October 7 at 7:52 AM
americanbankingnews.com logoMorgan Stanley Increases Regeneron Pharmaceuticals, Inc. (REGN) Price Target to $490.00
www.americanbankingnews.com - October 6 at 11:02 AM
streetinsider.com logoRegeneron (REGN) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case ... - StreetInsider.com
www.streetinsider.com - October 6 at 6:09 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Director Sells $712,500.00 in Stock
www.americanbankingnews.com - October 5 at 7:27 PM
fool.com logoWhy Regeneron Pharmaceuticals Dropped 11.3% in September
www.fool.com - October 5 at 10:44 AM
americanbankingnews.com logoInsider Selling: Regeneron Pharmaceuticals, Inc. (REGN) Director Sells 2,000 Shares of Stock
www.americanbankingnews.com - October 3 at 4:28 PM
finance.yahoo.com logoRegeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens
finance.yahoo.com - October 3 at 11:36 AM
finance.yahoo.com logoRegeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens
finance.yahoo.com - October 3 at 11:36 AM
finance.yahoo.com logoFDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta
finance.yahoo.com - October 3 at 11:36 AM
finance.yahoo.com logo3 Top-Ranked Big Biotech Stocks to Buy Now
finance.yahoo.com - October 3 at 11:36 AM
finance.yahoo.com logoAllergan's sNDA for Anti-Infective Avycaz Accepted by FDA
finance.yahoo.com - October 3 at 11:36 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Stock Rating Reaffirmed by SunTrust Banks, Inc.
www.americanbankingnews.com - October 2 at 5:08 PM
bloomberg.com logoRecent REGN News
www.bloomberg.com - September 29 at 11:01 PM
finance.yahoo.com logoShould You Sell Regeneron Pharmaceuticals Inc (REGN) At This PE Ratio?
finance.yahoo.com - September 29 at 11:01 PM
americanbankingnews.com logoRegeneron Pharmaceuticals' (REGN) "Overweight" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - September 29 at 11:28 AM
fool.com logo3 Stocks That Turned $7,000 Into $130,200
www.fool.com - September 28 at 8:25 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Earns "Hold" Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 27 at 6:52 PM
americanbankingnews.com logo Analysts Expect Regeneron Pharmaceuticals, Inc. (REGN) to Announce $3.86 Earnings Per Share
www.americanbankingnews.com - September 26 at 10:10 AM
nasdaq.com logoNotable Monday Option Activity: REGN, WHR, QRVO - Nasdaq
www.nasdaq.com - September 25 at 4:00 PM
finance.yahoo.com logoAbbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer
finance.yahoo.com - September 25 at 4:00 PM
finance.yahoo.com logoRegeneron Pharmaceuticals, Inc. :REGN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 22 at 3:56 PM
finance.yahoo.com logoETFs with exposure to Regeneron Pharmaceuticals, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 3:56 PM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Price Target Cut to $500.00 by Analysts at UBS AG
www.americanbankingnews.com - September 21 at 3:44 PM
barrons.com logoRegeneron's Biggest Long-Term Opportunity - Barron's
www.barrons.com - September 20 at 8:19 AM
seekingalpha.com logoRegeneron - Diversification Efforts Could Soon Yield Results - Seeking Alpha
seekingalpha.com - September 20 at 8:19 AM
finance.yahoo.com logo[$$] Regeneron's Biggest Long-Term Opportunity
finance.yahoo.com - September 20 at 8:19 AM
finance.yahoo.com logoRegeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
finance.yahoo.com - September 17 at 7:20 AM
americanbankingnews.com logoRegeneron Pharmaceuticals, Inc. (REGN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 8:40 PM
finance.yahoo.com logoAnalysts’ Recommendations for Regeneron in September 2017
finance.yahoo.com - September 15 at 11:18 PM
finance.yahoo.com logoRegeneron Is Focused on Increasing Awareness for Eylea in 2017
finance.yahoo.com - September 15 at 11:18 PM
finance.yahoo.com logoEylea Leads the Retinal Diseases Sector
finance.yahoo.com - September 15 at 11:18 PM
seekingalpha.com logoSwoop In To Pick Up Regeneron This Month - Seeking Alpha
seekingalpha.com - September 15 at 8:07 AM

Social

Chart

Regeneron Pharmaceuticals (REGN) Chart for Wednesday, October, 18, 2017

This page was last updated on 10/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.